|
Markt geschlossen -
Nasdaq
22:00:00 16.10.2026
|
Perf. 5 T | Veränd. 1. Jan. | ||
| 432.49 USD | -0.35% |
|
+4.25% | +32.13% |
| 16.10. | Panel der EU-Arzneimittelagentur befürwortet CuraTeQ Biologics' Neupogen-Biosimilar gegen Neutropenie | MT |
| 15.10. | Amgen Inc. : Bewertung von Goldman Sachs zum Kaufen erhalten | ZM |
ETFs investiert in Amgen Inc.
| Name | % 1. Jan. | Gewichtung | Volumen | |
|---|---|---|---|---|
 | +17.74% | - | 35 761 M€ | |
| +11.20% | - | 27 154 M€ | |
| +5.16% | - | 49 M€ | |
| +10.97% | - | 66 M€ | |
| +9.74% | - | 67 M€ | |
| +10.33% | - | 67 M€ | |
| +8.90% | - | 75 M€ | |
| +12.96% | - | 122 M€ | |
| +3.74% | - | 165 M€ | |
| +4.99% | - | 33 M€ | |
| +18.08% | - | 669 M€ | |
| +10.23% | - | 1 251 M€ | |
| +19.30% | - | 1 646 M€ | |
| +12.45% | - | 1 674 M€ | |
| +13.82% | - | 2 210 M€ | |
| +16.83% | - | 2 303 M€ | |
| +10.86% | - | 12 921 M€ | |
| +27.52% | 17.04% | 429 M€ | |
| +20.43% | 8.97% | 1 079 M€ | |
| +19.96% | 8.97% | 78 M€ | |
| +19.68% | 8.81% | 9 953 M€ | |
| +18.73% | 7.76% | 81 M€ | |
| +15.02% | 7.16% | 503 M€ | |
| -2.84% | 6.85% | 5 M€ | |
| +16.96% | 5.86% | 379 M€ | |
| +10.16% | 5.41% | 7 M€ | |
| 0.00% | 4.96% | 5 M€ |
Beschäftigte
31’500
Sektor
Pharmazeutika
Termine
- Börse
- Aktien
- 867900 Aktie
- ETFs Amgen Inc.
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
